Clinical trials: Rivaroxaban
Atrial Fibrillation
Non-interventional, Retrospective Cohort Study to Explore OAC Treatment in Korea
The primary purpose of this study is to evaluate comparative effectiveness and safety outcomes of therapies to prevent thromboembolic events in patients with nonvalvular atrial fibrillation by using Korean nationwide health…
- Trial name
- NCT03572972
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Where
- South Korea
- Volunteers
- 64,684 people
- Sponsor
- Pfizer
Type II Myocardial Infarction
Rivaroxaban in Type 2 Myocardial Infarctions
This trial is the pilot phase of a randomized controlled trial to test the feasibility of recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose rivaroxaban to reduce the risk of major…
- Trial name
- R2MI (NCT04838808)
- Testing
- Rivaroxaban 2.5 MG [Xarelto]
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University of Alberta
Atrial Fibrillation, Venous Thromboembolism
START-Register: Survey on Anticoagulated Patients Register
This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs).
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis
- Trial name
- NCT02219984
- Testing
- Anticoagulants
- Where
- Italy
- Volunteers
- 15,410 people
- Sponsor
- GUALTIERO PALARETI
Atrial Fibrillation, Rivaroxaban
Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Study Type and Design Prospective, Observational Study Rivaroxaban in Elderly AF patients with or without renal impairment in Korea This study will investigate effectiveness and safety in elderly patients, the result from…
- Conditions
- Atrial Fibrillation, Rivaroxaban, Elderly, Renal Insufficiency
- Trial name
- XAIENT (NCT04096547)
- Testing
- Rivaroxaban
- Where
- South Korea
- Volunteers
- 1,200 people
- Sponsor
- Samsung Medical Center
Deep Venous Thrombosis, Colonic Cancer
Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer
The chemoprophylaxis of deep vein thrombosis (DVT) with subcutaneous low-molecular-weight heparin (enoxaparin) in the postoperative period of elective surgeries is already well established in the literature and in clinical…
- Trial name
- Ésquilo (NCT05303818)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Hospital do Servidor Publico Estadual
Thromboses, Deep Vein, Surgery--Complications
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin
The main objective is to reduce the incidence of venous thromboembolism (VTE) in orthopedic postoperative patients based on the potential benefit of using rivaroxaban as a monotherapy.
- Trial name
- NCT03299296
- Testing
- Rivaroxaban 10 Milligrams, Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
- Volunteers
- 100 people
- Sponsor
- Ahmed AbdelMoneim Hassan Ali
Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation
CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention
This is a prospective, non-randomized, observational cohort study conducted at the FSBI "NMRC TPM" of the Ministry of Healthcare of the Russian Federation.
- Conditions
- Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, Left Atrial Appendage Closure, Hemorrhage
- Trial name
- CLOT-LESS (NCT07575867)
- Testing
- Left Atrial Appendage Closure, Apixaban 2.5 mg BID, Standard-dose DOAC
- Where
- Russia
- Volunteers
- 464 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Complications; Arthroplasty
Evaluation of Wound Drainage After Knee or Hip Arthroplasty
To compare side effects and complications relating to use of warfarin or rivaroxaban, tolerance and/or toxicity of these two agents such as drop in hemoglobin post operatively, extent of bruising, quantity of wound drainage…
- Trial name
- NCT02054936
- Testing
- Rivaroxaban (Xarelto), Warfarin (Coumadin)
- Where
- United States
- Sponsor
- University of Michigan
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Anticoagulants and Bleeding Disorders, Surgery
Oral Surgery in Patients Taking Direct Oral Anticoagulants
This study evaluates the incidence of postoperative bleeding after oral surgical procedures in patients taking direct oral anticoagulants and in patients taking vitamin K antagonists.
- Conditions
- Anticoagulants and Bleeding Disorders, Surgery, Postoperative Hemorrhage, Dentoalveolar Haemorrhage
- Trial name
- OSDOA (NCT04505475)
- Testing
- Oral surgical procedure followed by local hemostatic measures (insertion of gelatine sponge and wound suturing)
- Where
- Serbia
- Volunteers
- 82 people
- Sponsor
- University of Novi Sad
Pulmonary Embolism, Venous Thromboembolism
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a…
- Trial name
- STRATEGY-PE (NCT07603700)
- Testing
- Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Brain Ischemia
Xarelto [SPAF] Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Xarelto for SPAF.
- Trial name
- NCT01582737
- Testing
- Rivaroxaban(Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 11,310 people
- Sponsor
- Bayer
Coronary Artery Disease
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations.
- Trial name
- SWAP-AC (NCT04006288)
- Testing
- Clopidogrel, Prasugrel, ticagrelor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Florida
ST Segment Elevation Myocardial Infarction, Left Ventricular Thrombus
Prevention of Post-STEMI Left Ventricular Thrombus With Optimized Anticoagulant (EARLYmyo-LVT Ⅱ)
Left ventricular thrombus is a common complication subsequent to ST-segment elevation myocardial infarction (STEMI) that related to increased embolic events.
- Trial name
- NCT03786757
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Ischemic Stroke, Atrial Fibrillation Symptomatic
Cerebral Microbleeds During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)
Anticoagulants are generally recognized as a necessary therapy to prevent the recurrence of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF), but in some patients they also cause bleedings, particularly…
- Trial name
- CMB-NOW (NCT02356432)
- Where
- 3 sites in Japan
- Volunteers
- 86 people
- Sponsor
- Tokai University
Atrial Fibrillation, Anticoagulant Adverse Reaction
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.
- Trial name
- REVISE-AF (NCT06187311)
- Testing
- Rivaroxaban 20 MG, Rivaroxaban 15 MG
- Where
- South Korea
- Volunteers
- 940 people
- Sponsor
- Korea University Anam Hospital
Venous Thromboembolism, Major Bleed
Direct Oral Anticoagulants and Venous Thromboembolism
The purpose of this study is to determine whether use of direct oral anticoagulants (DOACs) is associated with an increased risk of major bleeding compared to warfarin use, for the treatment of venous thromboembolism (VTE).
- Trial name
- NCT02833987
- Testing
- Apixaban (ATC B01AF02), Dabigatran (ATC B01AE07), Rivaroxaban (ATC B01AF01)
- Where
- Canada
- Volunteers
- 59,525 people
- Sponsor
- Canadian Network for Observational Drug Effect Studies, CNODES
Chronic Kidney Disease, Acute Bleeding
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
Patients with severe chronic kidney disease (CKD) who develop atrial fibrillation are at high risk for stroke. The use of blood thinking medication in dialysis patients is controversial and warfarin carries a serious risk for…
- Conditions
- Chronic Kidney Disease, Acute Bleeding, Cerebrovascular Stroke
- Trial name
- STOP-HARM (NCT02885545)
- Testing
- Watchman, Continued therapy with the prescribed oral anticoagulant
- Where
- Canada
- Sponsor
- Population Health Research Institute
Coronary Artery Disease (CAD), Peripheral Arterial Disease (PAD)
Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk
Registry to describe the impact in terms of effectiveness and safety of the combination treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices in a real-life Dutch patient population that are…
- Trial name
- NCT04753372
- Testing
- Rivaroxaban 2.5 MG [Xarelto]
- Where
- 12 sites in Netherlands
- Volunteers
- 645 people
- Sponsor
- Maatschap Cardiologie Zwolle